Back to the future: oral targeted therapy for RA and other autoimmune diseases

O'Shea, J.J., Laurence, A. and McInnes, I.B. (2013) Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nature Reviews Rheumatology, 9(3), pp. 173-182. (doi:10.1038/nrrheum.2013.7) (PMID:23419429) (PMCID:PMC4169143)

Full text not currently available from Enlighten.


The molecular biology revolution coupled with the development of monoclonal antibody technology enabled remarkable progress in rheumatology therapy, comprising an array of highly effective biologic agents. With advances in understanding of the molecular nature of immune cell receptors came elucidation of intracellular signalling pathways downstream of these receptors. These discoveries raise the question of whether selective targeting of key intracellular factors with small molecules would add to the rheumatologic armamentarium. In this Review, we discuss several examples of this therapeutic strategy that seem to be successful, and consider their implications for the future of immune-targeted treatments. We focus on kinase inhibitors, primarily those targeting Janus kinase family members and spleen tyrosine kinase, given their advanced status in clinical development and application. We also summarize other targets involved in signalling pathways that might offer promise for therapeutic intervention in the future.

Item Type:Articles
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain
Authors: O'Shea, J.J., Laurence, A., and McInnes, I.B.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Nature Reviews Rheumatology
ISSN (Online):1759-4804

University Staff: Request a correction | Enlighten Editors: Update this record